Medical Device Clinical Trial Without CE Marking to Evidence Safety and Performance of the INBENTUS VERSATILE Ventilator in Patients Requiring Assisted/Controlled Mechanical Ventilation and Weaning.
INBENTUS VERSATILE: INBENTUS VERSATILE ventilation according to protocol specifications and clinical needs
Study summary
Pre-market clinical trial on 81 aldults participants to evidence safety and performance of the non-CE-marked medical device INBENTUS VERSATILE ventilator.
The 81 aldult participants are ventilated between 3 and 48 hours with invasive mechanical ventilation (IMV) in assisted/controlled mode and weaning under partial pressure support or volume support, followed by monitoring period until ICU discharge, hospital discharge or 30 days.
The study design differentiates between a Validation Cohort (up to 20 participants) for device validation and a Study Cohort (up to 61 participants) for safety and performance confirmation.
Serious Adverse Events related to study device and/or its procedure is defined as the primary safety endpoint, whereas technical failure rate is defined as the primary performance endpoint.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Participants ≥ 18 years of age at the time of consent.
* Participants requiring invasive mechanical ventilation for a period of ≥3 hours.
* Participants must provide written informed consent.
Exclusion Criteria:
1. Participants requiring anesthetic delivery systems or aerosol nebulizer systems.
2. Participants requiring modifications to the ventilator circuit, such as those treated with nitric oxide (iNO).
3. Any participant determined by the research team to be hemodynamically unstable, defined as:
1. MAP \< 65 mmHg despite vasoactive drugs.
2. Systolic Blood Pressure \> 180 mmHg.
3. Diastolic Blood Pressure \> 110 mmHg.
4. Severe volume loss (\>30% of blood volume) with persistent signs of hypoperfusion.
4. Life expectancy of less than 12 months.
5. Pregnant women at the time of informed consent.
Primary outcome measure(s)
Primary Safety Endpoint — From 3 to 48 hours of mechanical ventilation under the study device Serious adverse events related to INBENTUS VERSATILE is defined as the primary safety endpoint
Primary Performance Endpoint — From 3 to 48 hours of mechanical ventilation under the study device Technical failure rate of INBENTUS VERSATILE is defined as the primary performance endpoint
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.